Benitec Biopharma Inc. (NASDAQ:BNTC)

Benitec Biopharma Inc. BNTC

Healthcare - Biotechnology - NASDAQ - US

Watchlist

$ 10.68

2.69 %

$ 212 M

Market Cap

-1.94

P/E

1. INTRINSIC VALUE

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.[ Read More ]

The intrinsic value of one BNTC stock under the base case scenario is HIDDEN Compared to the current market price of 10.7 USD, Benitec Biopharma Inc. is HIDDEN

BNTC Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart BNTC

FINANCIALS

Annual
Quarterly

216 K REVENUE

Growth Rates

1Year 188.00%

3Years 54.12%

5Years -54.69%

7Years -9.96%

10Years -14.36%

-22.5 M OPERATING INCOME

Growth Rates

1Year -17.87%

3Years -18.27%

5Years -65.00%

7Years -5.06%

10Years -4.56%

-21.8 M NET INCOME

Growth Rates

1Year -11.19%

3Years -16.15%

5Years -56.33%

7Years -25.76%

10Years -7.22%

-19.4 M OPERATING CASH FLOW

Growth Rates

1Year -7.72%

3Years -14.78%

5Years -38.25%

7Years -12.89%

10Years -7.19%

-179 K INVESTING CASH FLOW

Growth Rates

1Year -17800.00%

3Years 6.78%

5Years 14.82%

7Years 3.64%

10Years 9.31%

68 M FINANCING CASH FLOW

Growth Rates

1Year 324.78%

3Years 44.55%

5Years 151.62%

7Years 41.13%

10Years 106.20%

0 REVENUE

Growth Rates

1Year 188.00%

3Years 54.12%

5Years -54.69%

7Years -9.96%

10Years -14.36%

-5.79 M OPERATING INCOME

Growth Rates

1Year -17.87%

3Years -18.27%

5Years -65.00%

7Years -5.06%

10Years -4.56%

-5.06 M NET INCOME

Growth Rates

1Year -11.19%

3Years -16.15%

5Years -56.33%

7Years -25.76%

10Years -7.22%

-4.59 M OPERATING CASH FLOW

Growth Rates

1Year -7.72%

3Years -14.78%

5Years -38.25%

7Years -12.89%

10Years -7.19%

0 INVESTING CASH FLOW

Growth Rates

1Year -17800.00%

3Years 6.78%

5Years 14.82%

7Years 3.64%

10Years 9.31%

21.7 M FINANCING CASH FLOW

Growth Rates

1Year 324.78%

3Years 44.55%

5Years 151.62%

7Years 41.13%

10Years 106.20%

Balance Sheet Decomposition Benitec Biopharma Inc.

52.2 M ASSETS
4.96 M LIABILITIES

Current Assets	51.7 M
Cash & Short-Term Investments	50.9 M
Receivables	0
Other Current Assets	808 K
Non-Current Assets	536 K
Long-Term Investments	0
PP&E	449 K
Other Non-Current Assets	87 K

Current Liabilities	4.92 M
Accounts Payable	1.35 M
Short-Term Debt	284 K
Other Current Liabilities	3.29 M
Non-Current Liabilities	38 K
Long-Term Debt	0
Other Non-Current Liabilities	38 K

EFFICIENCY

Earnings Waterfall Benitec Biopharma Inc.

Revenue	216 K
Cost Of Revenue	108 K
Gross Profit	108 K
Operating Expenses	22.4 M
Operating Income	-22.5 M
Other Expenses	-739 K
Net Income	-21.8 M

RATIOS

50.00% GROSS MARGIN

Averages

1Year 50.00%

3Years -90.11%

5Years -111.03%

7Years -61.67%

10Years -21.17%

-10412.04% OPERATING MARGIN

Averages

1Year -10412.04%

3Years -20103.63%

5Years -18378.42%

7Years -13393.16%

10Years -10610.02%

-10069.91% NET MARGIN

Averages

1Year -10069.91%

3Years -20526.66%

5Years -18699.07%

7Years -13621.06%

10Years -10272.32%

-46.04% ROE

Averages

1Year -46.04%

3Years -3458.09%

5Years -2104.84%

7Years -1509.86%

10Years -1077.52%

-41.66% ROA

Averages

1Year -41.66%

3Years -263.55%

5Years -185.35%

7Years -138.05%

10Years -116.11%

-46.28% ROIC

Averages

1Year -46.28%

3Years -3375.11%

5Years -2054.78%

7Years -1474.33%

10Years -1059.20%

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Benitec Biopharma Inc.

Net Income	-21.8 M
Depreciation & Amortization	343 K
Capital Expenditures	-179 K
Stock-Based Compensation	830 K
Change in Working Capital	1.17 M
Others	234 K
Free Cash Flow	-19.6 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Benitec Biopharma Inc.

Wall Street analysts predict an average 1-year price target for BNTC of $19.2 , with forecasts ranging from a low of $13 to a high of $30 .

BNTC Lowest Price Target Wall Street Target

13 USD 21.72%

BNTC Average Price Target Wall Street Target

19.2 USD 80.24%

BNTC Highest Price Target Wall Street Target

30 USD 180.90%

4. DIVIDEND ANALYSIS

0.00% DIVIDEND YIELD

0.765 USD DIVIDEND PER SHARE

5. COMPETITION

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States.

1.96 USD

BPTH

Undervalued 141.78%

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.

-12.4 USD

CAPR

Overvalued 166.70%

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

0.233 USD

NXTC

Overvalued 82.24%

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer.

-2.09 USD

EFTR

Overvalued 1044932.22%

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.

3.75 USD

ALRN

Undervalued 30.81%

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

3.02 USD

ZURA

Overvalued 4.48%

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases.

3.21 USD

ZVSA

Undervalued 197.14%

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia.

0.368 USD

APLM

Undervalued 283.97%

6. Ownership

Insider Ownership Benitec Biopharma Inc.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price
1 year ago Aug 11, 2023	Bought 2.59 USD	Boston Megan Executive Director	+ 25907	0.0001 USD
1 year ago Aug 11, 2023	Bought 100 K USD	Boston Megan Executive Director	+ 25907	3.86 USD
1 year ago Aug 11, 2023	Bought 5.18 USD	BUCHI J KEVIN Director	+ 51813	0.0001 USD
1 year ago Aug 11, 2023	Bought 200 K USD	BUCHI J KEVIN Director	+ 51813	3.86 USD
2 years ago Dec 09, 2021	Bought 32.1 K USD	Oliveira Steven Michael 10 percent owner	+ 10553	3.0443 USD
2 years ago Nov 29, 2021	Bought 121 K USD	Oliveira Steven Michael 10 percent owner	+ 37947	3.1804 USD
3 years ago May 03, 2021	Bought 172 K USD	Oliveira Steven Michael 10 percent owner	+ 40500	4.2537 USD
3 years ago Apr 30, 2021	Bought 502 K USD	Oliveira Steven Michael 10 percent owner	+ 120000	4.1824 USD
3 years ago Apr 29, 2021	Bought 126 K USD	Oliveira Steven Michael 10 percent owner	+ 22877	5.491 USD
3 years ago Apr 28, 2021	Bought 545 K USD	Oliveira Steven Michael 10 percent owner	+ 100000	5.4486 USD

7. News

Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update -Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29 th Annual Congress of the World Muscle Society- globenewswire.com - 2 days ago

Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024. globenewswire.com - 1 week ago

Benitec Biopharma: OPMD Program Continues To Advance With Catalysts Benitec Biopharma Inc.'s BB-301 showed positive interim results in treating OPMD, allowing for higher dosing in 2025 and a potential late-stage trial in 2026. BB-301 demonstrated significant improvements in swallowing function and reduced pharyngeal residue, with no serious adverse events reported in the phase 1b/2a study. Financially, Benitec Biopharma is well-positioned with $50.9 million in cash, sufficient to fund operations through 2025, thanks to a $40 million PIPE financing. seekingalpha.com - 1 month ago

Benitec Biopharma Announces Updated Investor Webcast Information -Management plans to host an investor webcast on October 14 th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- globenewswire.com - 1 month ago

Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society -Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing- globenewswire.com - 1 month ago

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update -Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July- globenewswire.com - 1 month ago

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that a Late Breaking Abstract on BB-301 was accepted for oral presentation at the 29th Annual Congress of the World Muscle Society, taking place in Prague, Czech Republic from October 8-12, 2024. The Late Breaking Abstract entitled “Interim Clinical Data Summary: A Phase 1b/2a Open-label, Dose Escalation Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of an AAV9-based gene therapy (BB-301) Administered to Subjects with Oculopharyngeal Muscular Dystrophy (OPMD) with Dysphagia” will be presented on October 12, 2024. globenewswire.com - 1 month ago

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study -The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose of gene therapy BB-301 as compared to the pre-dose average values recorded for Subject 1 during the OPMD Natural History Study- globenewswire.com - 4 months ago

Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update -Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April- globenewswire.com - 6 months ago

Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study -First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- globenewswire.com - 7 months ago

Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share of $4.80, and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 2,584,239 shares of its common stock at a price per pre-funded warrant of $4.7999, to certain institutional accredited investors. The oversubscribed financing was led by Suvretta Capital Management, LLC (“Suvretta Capital”) with participation from new and existing investors including Adage Capital Partners L.P., Nantahala Capital, multiple healthcare-focused funds, and a leading mutual fund. Gross proceeds from the PIPE financing total approximately $40.0 million, before deducting offering expenses. The closing price of the Company's common stock on April 17, 2024 was $4.80. globenewswire.com - 7 months ago

Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update -First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit- -Second Subject Scheduled to Receive BB-301 in February 2024- -23 Subjects Enrolled into the Oculopharyngeal Muscular Dystrophy Natural History Study with Multiple Subjects Eligible for entry into the Phase 1b/2a Clinical Treatment Study in 2024- HAYWARD, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its second fiscal quarter ended December 31, 2023. globenewswire.com - 9 months ago

8. Profile Summary

Benitec Biopharma Inc. BNTC

COUNTRY US

INDUSTRY Biotechnology

MARKET CAP $ 212 M

Dividend Yield 0.00%

Description Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Contact 3940 Trust Way, Hayward, CA, 94545 https://benitec.com

IPO Date June 24, 2014

Employees 16

Officers Dr. Jerel A. Banks M.D., Ph.D. Executive Chairman & Chief Executive Officer Ms. Megan Joan Boston B.Com., C.A. Executive Director Dr. Michael Graham Head of Discovery & Founding Scientist Dr. Claudia Kloth Ph.D. Senior Vice President of Manufacturing

Price Chart BNTC

Benitec Biopharma Inc. BNTC

Premium Plan

Unlimited Plan